Cingulate CEO Shane J. Schaffer Granted Stock Options with FDA Approval Contingency

Cingulate Inc. CEO Shane J. Schaffer was granted 295,000 stock options on July 16, 2026, with an exercise price of $4.43 per share and expiration in 2036. The options consist of two grants: 197,650 options vesting 25% on March 31, 2027, with the remainder vesting monthly over 36 months, and 97,350 options with additional FDA approval contingencies. The second grant's vesting is contingent on FDA approval of the company's NDA for CTx-1301 during 2027. If FDA approval is not obtained in 2027, the entire second grant (including any vested portion) will terminate. This filing represents a significant equity compensation award to the CEO with performance-based conditions tied to regulatory approval of a key drug candidate.